Why the study?
Does Losartan reduce cardiovascular events in patients with hypertension and left ventricular hypertrophy?
Does Losartan reduce cardiovascular events in patients with hypertension and left ventricular hypertrophy?
This review highlights that losartan is effective for reducing cardiovascular events in patients with hypertension and left ventricular hypertrophy, though this benefit may not extend to black patients.
May not extend losartan benefit to black patients with hypertensive LVH; leaves open need for race-specific prospective trials.
Losartan is an orally active, selective, nonpeptide, angiotensin-II Type I-receptor antagonist, and was the first drug marketed in this class. It has been approved for the treatment of hypertension, and may be used alone or in combination with other antihypertensive agents. Based on the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, losartan has been approved for the reduction of cardiovascular events in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. Based on the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study, losartan is also indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria, in patients with Type 2 diabetes. The focus of this review is the LIFE study.
No takes yet. Share an insight, caveat, or question.
Devereux et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: